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ABSTRACT
Background
In multiple sclerosis, inflammation can successfully be prevented, while promoting repair is
still a major challenge. Microglial cells, the resident phagocytes of the central nervous system
(CNS), are hematopoietic-derived myeloid cells and express the triggering receptor expressed
on myeloid cells 2 (TREM2), an innate immune receptor. Myeloid cells are an accessible source
for ex vivo gene therapy. We investigated whether myeloid precursor cells genetically modified
to express TREM2 affect the disease course of experimental autoimmune encephalomyelitis
(EAE), an animal model of multiple sclerosis.
Methods and Findings
EAE was induced in mice by immunization with a myelin autoantigen. Intravenous
application of TREM2-transduced bone marrow–derived myeloid precursor cells at the EAE
peak led to an amelioration of clinical symptoms, reduction in axonal damage, and prevention
of further demyelination. TREM2-transduced myeloid cells applied intravenously migrated into
the inflammatory spinal cord lesions of EAE-diseased mice, showed increased lysosomal and
phagocytic activity, cleared degenerated myelin, and created an anti-inflammatory cytokine
milieu within the CNS.
Conclusions
Intravenously applied bone marrow–derived and TREM2-tranduced myeloid precursor cells
limit tissue destruction and facilitate repair within the murine CNS by clearance of cellular
debris during EAE. TREM2 is a new attractive target for promotion of repair and resolution of
inflammation in multiple sclerosis and other neuroinflammatory diseases.
The Editors’ Summary of this article follows the references.
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Hematopoietic-derived myeloid cells physiologically mi-
grate into the central nervous system (CNS) not only during
development, but also in adulthood, and become resident
perivascular macrophages and microglia [1–3]. Data suggest
that there is a continuous and lifelong turnover of perivas-
cular brain macrophages replenished by bone marrow–
derived cells. Furthermore, it has been demonstrated that
bone marrow cells are recruited to sites of axonal degener-
ation [4,5] or to beta-amyloid depositions in Alzheimer
disease animal models [6,7] to become functional microglia-
like cells. The exact cellular subtype of myeloid precursors
developing into microglia is not known, but parenchymal
microglial cells have been reported to be phenotypically very
similar to uncommitted myeloid precursors having ‘‘empty’’
major histocompatibility complex (MHC) class II, comparable
cystein protease proﬁles, and the capacity to differentiate
into dendritic-like cells [8,9]. Thus, bone marrow–derived
myeloid cells (BM-MC) might reﬂect microglial precursors
and may serve as a natural vehicle for CNS cell and gene
therapy [2,10].
Efﬁcient removal of apoptotic cells and cellular debris by
macrophages during acute injury or degenerative diseases is
essential for repair of the damaged tissue, inﬂammation
resolution, and disease recovery [11–13]. Recently, we
discovered in vitro that the microglial triggering receptor
expressed on myeloid cells-2 (TREM2) stimulates phagocy-
tosis and down-regulates inﬂammatory signals in microglia
via the signaling adaptor molecule DAP12 [14]. Both
clearance of tissue debris by phagocytosis and a protective
cytokine milieu have been implicated as positive factors for
tissue repair in multiple sclerosis (MS) [15]. Furthermore, the
microglial cytokine milieu determines the outcome of the
inﬂammatory process in the animal model of MS, exper-
imental autoimmune encephalomyelitis (EAE) [16–18]. There-
fore, clearance of cellular debris and resolution of
inﬂammation are important for recovery and repair in
neuroinﬂammatory diseases.
Methods
Isolation and Flow Cytometry Analysis of Microglia
Derived from the CNS
Cortex, cerebellum, and spinal cord of normal or EAE-
diseased mice were isolated and homogenized. Homogenates
were ﬁltrated through a 40-lM nylon mesh in a 50-ml tube,
diluted with PBS and centrifuged (1,500 rpm) at room
temperature for 5 min. Microglia and macrophages were
separated through a density gradient. The cells were
suspended in 70% Percoll (Amersham Biosciences, http://
www.amershambiosciences.com) and overlaid with 37% and
30% gradient. The density gradient was centrifuged at 2,000
rpm for 30 min at room temperature. Myelin collected in the
30% Percoll layer was removed. The majority of microglia/
macrophages were found in the interface of 37% and 70%
Percoll. Cells were obtained from this interface and were
washed from the Percoll with PBS. Cells were conﬁrmed to be
microglia/macrophages by ﬂow cytometry analysis with
speciﬁc biotinylated antibodies directed against CD11b (BD
Biosciences Pharmingen, http://www.bdbiosciences.com) fol-
lowed by streptavidin-PE (Dianova, http://www.dianova.de).
For ﬂow cytometry analysis, cells were incubated with a
monoclonal rat anti-mouse TREM2 antibody (R&D Systems,
http://www.rndsystems.com) and visualized with goat anti-rat
FITC (Dianova).
Isolation and Culture of BM-MC
Isolation of myeloid precursors was performed by a
modiﬁed method published by Willenbring and collaborators
[19]. In detail, bone marrow cells were isolated from adult 6–
8-wk-old female C57BL/6 mice (Charles River, Sulzfeld,
Germany) from the medullary cavities of the tibia and femur
of the hind limbs. Removal of erythrocytes was performed by
lysis with hypotonic solution. Cells were cultured in DMEM
medium (Invitrogen, http://www.invitrogen.com) containing
10% fetal calf serum (Pan Biotech, http://www.pan-biotech.
com) and 10 ng/ml of granulocyte macrophage–colony
stimulating factor (GM-CSF) (R&D Systems) in 75-cm
2 culture
ﬂasks (Greiner Bio-One, http://www.gbo.com). After 24 h,
non-adherent cells were collected and re-seeded in fresh 75-
cm
2 culture ﬂasks. Medium was changed after 5 d and BM-MC
were collected for experiments after 10–11 d.
Isolation and Culture of Monocytes
Peripheral blood was collected from adult C57BL/6 mice.
Erythrocytes were depleted by hypotonic lysis buffer. Cells
were plated on culture dishes in RPMI medium (Invitrogen)
containing 10% fetal calf serum (Pan Biotech). Cells were
cultured for several hours at 37 8C in 10% CO2. After
trypsinization, adherent cells were collected and used for
phagocytosis experiments.
Lentiviral Vector System and Bone Marrow–Derived
Myeloid Cell Transduction
Lentiviral vectors of the third generation, (pLenti6/V5,
Invitrogen) were used for transduction of BM-MC. The
blasticidin-resistance gene in the pLenti6/V5 vector was
replaced by a second cytomegalovirus (CMV) promoter, and
the green ﬂuorescent protein (GFP) gene was subcloned
downstream of the TREM2 gene, which was obtained from
primary murine microglia and placed under the original
CMV promoter. The correct nature of all cloned sequences
was conﬁrmed by automated sequencing (Seqlab, Go ¨ttingen,
Germany). Lentiviral transduction was performed as de-
scribed [14]. Titers of concentrated viral particles ranged
between 1 3 10
8 and 1 3 10
9 transducing units/ml. Lentiviral
particles and 6 lg/ml polybrene (Sigma, http://www.
sigmaaldrich.com) were added at day 2 to cultured BM-MC.
Supernatant was removed 24 h after infection and replaced
with DMEM medium containing 10% fetal calf serum with
GM-CSF. In all experiments, the efﬁciency of BM-MC trans-
duction was .90% as determined by the number of BM-MC
expressing the GFP molecule and by immunohistochemistry.
Flow Cytometry Analysis of BM-MC
BM-MC transduced with the TREM2 vector or the control
GFP vector were ﬁrst incubated for Fc-receptor blockade by
CD16/CD32 antibody (BD Biosciences Pharmingen) and then
stained with either biotin-conjugated anti-CD45, anti-CD11b,
anti-CD11c, anti-CD86, anti-CD80, anti-I-A
b (MHC class II),
anti-CD36, anti-Sca-1, anti-c-kit, anti-CD133 (BD Biosciences
Pharmingen), anti-F4/80 (Serotec Laboratories, http://
www.serotec.com), or anti-mouse CCR7 (Alexis, Lausen,
Switzerland) followed by CyChrome-conjugated streptavidin
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IgG and Cy5-conjugated streptavidin (Dianova). Furthermore,
cells were stained with anti-TREM2 monoclonal antibodies
(R&D Systems) followed by biotin-conjugated anti-rabbit IgG
(Dianova) and CyChrome-conjugated streptavidin (BD Bio-
sciences Pharmingen). Cells obtained from EAE spinal cord
were stained with anti-CD45 antibody (BD Biosciences
Pharmingen) and CyChrome-conjugated streptavidin (BD
Biosciences Pharmingen), or with anti-TREM2 monoclonal
antibody followed by biotin-conjugated anti-rabbit IgG and
CyChrome-conjugated streptavidin. Isotype-matched control
antibodies (Sigma) were used as negative control. Analysis was
done with a FACScalibur ﬂow cytometer (BD Biosciences
Pharmingen). Live gating was performed with propidium
iodide (Sigma).
RT-PCR Analysis of TREM2 and DAP12 Gene Transcripts
RNA was isolated from BM-MC by RNeasy Mini Kit
(Qiagen, Valencia, California, United States). Reverse tran-
scription of RNA was performed with SuperScript III reverse
transcriptase (Invitrogen) and hexamer random primers
(Roche Molecular Biochemicals, Mannheim, Germany). For
semi-quantiﬁcation, all samples were normalized with
GAPDH ampliﬁcation.
Western Blot Analysis of ERK
BM-MC were transduced with the TREM2 vector. Then 23
10
5 cells were cultured on dishes, pre-coated with 10 lg/ml
monoclonal antibody directed against TREM2 (R&D Systems)
or with 10 lg/ml isotype control antibody (Sigma). After
stimulation for 1 h, cells were lysed in reducing sample buffer
for Western blot analysis. Phosphorylation of ERK and the
total amount of ERK were determined by immunodetection
with anti-phospho-ERK and anti-ERK antibodies, respectively
(both from Cell Signaling Technology, Beverly, Massachusetts,
United States).
Microsphere Bead-Phagocytosis Assay
BM-MC were transduced with the TREM2 vector or the
control GFP vector. Transduced BM-MC or cultured mono-
cytes (5 3 10
4) obtained from peripheral blood of C57BL/6
mice were cultured on dishes that had been pre-coated with
10 lg/ml monoclonal antibody directed against TREM2 (R&D
Systems) or with 10 lg/ml isotype control antibody (Sigma).
After 1 h, 100 ll of red ﬂuorescent microsphere beads
solution (Fluoresbrite Polychromatic Red Microspheres, 1.00
lm, Polysciences; http://www.polysciences.com) was added to
1 ml of cultured cells for 1 h. After a washing step, all cells
from three independent ﬁelds (at 633 magniﬁcation) were
counted under a ﬂuorescence microscope, and phagocytosis
of microsphere beads by BM-MC or cultured monocytes was
analyzed. Relative change in phagocytosis was observed due
to interexperimental variations. Data are shown as the
relative change in phagocytosis between cells cultured on
anti-TREM2 antibody and control antibody. For phagocytosis
of apoptotic neural cells, the percentage of phagocytosis (the
number of phagocytes having taken up at least two beads/the
number of all BM-MC 3 100) was calculated. After counting
the number of cells under a ﬂuorescence microscope, cells
were collected and the percentage of GFPþ(green signal) plus
beadþ (red signal) was quantiﬁed by ﬂow cytometry. The
threshold for deﬁning the uptake of at least two beads was
determined by the intensity of the ﬂow cytometry signal. The
relative change in phagocytosis was determined due to
interexperimental variations. Data are shown as the relative
change in phagocytosis between cells cultured on anti-
TREM2 antibody and control antibody. In blocking experi-
ments, ERK inhibitor PD98059 (20 lM) (Calbiochem, http://
www.emdbiosciences.com/g.asp?f¼CBC/home.html) was added
60 min before stimulation of TREM2.
Phagocytosis Assay of Apoptotic Neurons
Neuron-enriched cells were derived from embryonic E18
mouse (C57BL/6) hippocampus and cultured for 5–10 d.
Okadaic acid was added for 3 h at a concentration of 30 nM
to induce apoptosis. Apoptotic cell membranes were labeled
with CellTracker CM-DiI membrane dye (http://probes.
invitrogen.com). After incubation, apoptotic cells were
washed twice and added to the transduced myeloid precursor
culture or cultured monocytes at an effector:target ratio of
1:20. One hour after the addition of apoptotic cells, the
number of BM-MC or cultured monocytes having phagocy-
tosed apoptotic cell membranes was counted under a
confocal ﬂuorescence microscope (Leica, Wetzlar, Germany).
Apoptotic cells were counted in three different areas at 603
magniﬁcation. The amount of phagocytosis was also con-
ﬁrmed by ﬂow cytometry. In blocking experiments, ERK
inhibitor PD98059 (20 lM) (Calbiochem) was added 60 min
before stimulation of TREM2. Moreover, 48 h after the
addition of apoptotic neuron–enriched cultures, the cells
were collected and used for semiquantitative real-time RT-
PCR of inﬂammatory gene transcripts.
Analysis of Inflammatory Gene Transcripts by Real-Time
RT-PCR
RNA was isolated by the RNeasy Mini Kit (Qiagen) from 23
10
5 TREM2 or GFP-transduced myeloid precursors after
cross-linking by TREM2-speciﬁc antibodies for 1 h followed
by addition of 100 ng/ml lipopolysaccharide (LPS) (Sigma) or
coculturing with apoptotic cells. Furthermore, RNA was
isolated from total spinal cord, peritoneal lymph nodes, and
spleen of EAE-diseased mice 2 d after intravenous application
of TREM2-transduced BM-MC, GFP-transduced BM-MC, or
PBS control (6 d after ﬁrst clinical signs of EAE). Reverse
transcription of RNA was performed with SuperScript III
reverse transcriptase (Invitrogen) and hexamer random
primers (Roche Molecular Biochemicals). Quantitative RT-
PCR with speciﬁc oligonucleotides was performed with Test
SYBR Green PCR Master Mix (Qiagen) using the ABI 5700
Sequence Detection System (Perkin Elmer, http://www.
amebioscience.com) and ampliﬁcation protocol for the ABI
5700 Sequence Detection System. Ampliﬁcation speciﬁcity
was proven by a melting curve. Results were analyzed with the
ABI 5700 Sequence Detection System v.1.3 after establishing
the reaction efﬁciency for each primer pair. Quantiﬁcation
using the delta-CT method was carried out, and standard
curves were used for each plate.
ELISA Assay for Interleukin-10
Enzyme-linked immunosorbent assay (ELISA) for interleu-
kin-10 (IL-10) was used to determine the levels of IL-10
released from myeloid cells after stimulation. TREM2 or GFP-
transduced myeloid precursors were stimulated by cross-
linking TREM2-speciﬁc antibodies for 1 h followed by
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apoptotic cells. Supernatant was collected after 24 h, and the
level of IL-10 was determined by ELISA according to the
manufacturer’s instructions (QuantikineM mouse IL-10, R&D
Systems).
Induction and Cell Therapy of EAE
Adult 7–9-wk-old female C57BL/6 mice (obtained from
Charles River Laboratories, http://www.criver.com) were
injected in the tail base bilaterally with 200 llo fa n
innoculum containing 100 lg of myelin oligodendrocyte
glycoprotein peptide 35–55 (amino acids MEVG-
WYRSPFSRVVHLYRNGK; Seqlab) and 1 mg of Mycobacterium
tuberculosis H37 Ra (Difco, http://www.bd.com) in incomplete
Freund adjuvant (Difco). Pertussis toxin (200 ng; List Bio-
logical Laboratories, http://www.listlabs.com) was injected at
day 0 and at day 2 after immunization. Clinical signs were
scored as follows: 0, no clinical signs; 1, complete limp tail; 2,
complete limp tail and abnormal gait; 3, one hind-limb
paraparesis; 4, complete hindlimb paraparesis; 5, fore- and
hind-limb paralysis or moribund. Only mice having disease
onset (clinical score of 1 or more) at day 14 were used for
experiments. TREM2-transduced (5 3 10
6 cells in PBS), GFP-
transduced BM-MC (5 3 10
6 cells in PBS), or vehicle control
(PBS) were injected intravenously under light anesthesia in
EAE-diseased mice at the day of the ﬁrst clinical symptoms, or
at day 4 after ﬁrst clinical symptoms.
Immunohistochemistry
Animals were perfused transcardially with 0.125 M PBS
followed by 4% paraformaldehyde. After post-ﬁxation in
fresh ﬁxative, tissue was cryoprotected at 4 8C in 0.125 M PBS
containing 2% DMSO and 10% glycerol. Tissue was embed-
ded in OCT (Sakura, http://www.sakura.com), frozen on dry
ice, and stored at  80 8C before cryosectioning on a Leica
CM1900 cryostat at  20 8C. For Iba1 and CD45 staining,
sections were reﬁxed in 4% paraformaldehyde for 1 h and
then immunostained with puriﬁed polyclonal rabbit antibody
directed against Iba1 (Wako, http://www.wako-chem.co.jp/
english/labchem/productinf.htm) and secondary-ﬂuorescence
Cy3-conjugated antibody directed against rabbit IgG (1:200,
Dianova), or with monoclonal antibody directed against
CD45 (1:100, BD Biosciences Pharmingen) and a secondary-
ﬂuorescence Cy3-conjugated antibody directed against rat
IgG (1:200, Dianova). For lysosome-associated membrane
protein 2 (Lamp2) staining, sections were reﬁxed in methanol
for 5 min and then immunostained by monoclonal rat
antibody directed against Lamp2 (1:100, Abcam, Hiddenhau-
sen, Germany) and a secondary-ﬂuorescence Cy3-conjugated
antibody directed against rat IgG (1:200). Fluorescence
images were collected by confocal laser scanning microscopy
with a 403 objective (Leica). For quantiﬁcation of Lamp2-
positive cells, random images from frozen sections were
scanned by a blinded observer and analyzed by another
blinded observer. Random images from frozen sections of
different time points after cell injection were also used to
count the numbers of GFPþ cells that had migrated into the
spinal cord.
Histological examination of immune cell inﬁltrates, axonal
injury, and demyelination was performed as described
previously [20]. In brief, mice were perfused with 4%
paraformaldehyde in PBS at indicated time points. After
removal of the spinal cord and ﬁxation in 4% buffered
formalin, spinal cord was dissected and embedded in parafﬁn.
After microwave pretreatment in 10 mM citric acid, the
following antibodies were used for immunohistochemical
analysis of the spinal cord tissue: monoclonal rat anti-mouse
MAC3 (clone M3/84, dilution: 1:200, BD Biosciences Phar-
mingen) for macrophage staining, monoclonal rat anti-
human/mouse CD3 (clone CD3–12, dilution: 1:200, Serotec
Laboratories) for T cells, monoclonal mouse anti-amyloid
precursor protein (APP) (clone 22C11, dilution: 1:100,
Chemicon, Temecula, California, United States) for axonal
degeneration, monoclonal mouse anti-SMI 32 (dilution: 1:200,
Sternberger Monoclonals, Lutherville, Massachusetts, United
States) for the detection of dephosphorylated neuroﬁlament,
and polyclonal rabbit anti-myelin basic protein (dMBP,
AB5864, dilution 1:2000, Chemicon) for degraded MBP. The
following secondary antibodies were utilized: for CD3 and
MAC3, a biotinylated goat anti-rat immunoglobulin
(RPN1005, dilution 1:200, Amersham Biosciences) and for
APP, SMI32 sheep anti-mouse immunoglobulin (RPN1001,
dilution 1:200, Amersham Biosciences). Immunohistochemis-
try was processed by using the avidin–biotin ampliﬁcation
bridge method with peroxidase as a substrate.
Inﬂammatory spinal cord lesions were deﬁned in each
animal on the basis of the MAC3 staining and were further
analyzed by immunohistochemistry and luxol fast blue (LFB)
staining. The number of MAC3þ cells, CD3þ cells, APP and
dMBP-positive deposits, SMI-positive axons, and the level of
demyelination in LFB staining were quantiﬁed on three
lumbal spinal cord sections in at least three mice per group
using an Olympus BX51 microscope (Olympus, Hamburg,
Germany) equipped with a digital camera (SIS Color View)
attached to a computer with software for image analysis
(AnalySIS; Soft Imaging System, http://www.soft-imaging.net).
Quantiﬁcation of MAC3þ cells, CD3þ cells, APP- and dMBP-
positive deposits was performed by a blinded observer.
In LFB staining, total white matter and demyelinated areas
from three cross sections were measured by planimetry, and
the area of demyelination was expressed as a percentage of
the total area of the white matter. Decreased LFB staining
represents either demyelination or a loss of myelin due to
axonal destruction. For each animal, the mean percentage of
demyelination of the individual sections was calculated.
In SMI32 staining, the relative number of dephosporylated
axons in the spinal cord white matter was determined using
an axon grid (Olympus) under 31,000 magniﬁcation. Thus,
the relative number of SMI32-positive axons covered by 25
crosses per grid was counted in at least seven eye ﬁelds per
mouse (n ¼ 3 mice per group).
Statistical Analysis
Data were analyzed by SPSS software (Statistical Package for
Social Sciences version 14.0 for Windows; http://calcnet.mth.
cmich.edu/org/spss/index.htm). Analysis of variance (ANOVA)
was applied to experiments with three or more experimental
groups. Groups showing differences after testing with
ANOVA were re-analyzed by pairwise t-test. The p-values
presented throughout the Results are derived from the
pairwise t-test, with the exception of the ANOVA results that
gave a higher p-value. The sample sizes in animal experiments
were preplanned taking into consideration the German
animal protection law.
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Expression of TREM2 within the CNS
TREM2 has been shown to be expressed on certain
subtypes of myeloid cells, particularly osteoclasts, immature
dendritic cells, and microglia [21]. To study the expression
kinetics of TREM2 during EAE, we performed ﬂow cytometry
analysis of TREM2 on freshly isolated microglia and resident
CNS cells identiﬁed by immmunostaining for CD11b. Flow
cytometry analysis demonstrated TREM2 expression on a
minority of microglial cells under normal conditions in adult
C57BL/6 mice (Figure 1A). Next, we induced EAE by
immunization with the myelin oligodendrocyte glycoprotein
peptide 35–55. At day 4 after onset of clinical symptoms of
EAE, TREM2 was detected on approximately half of the
CD11bþ cells in the spinal cord, the tissue region mostly
affected by the inﬂammatory lesions (Figure 1A and 1B). In
detail, the percentage of TREM2 and CD11bþ cells in the
spinal cord increased from 23.3% (standard error of the
mean [SEM] 16.1) in the normal tissue to 58.8% (SEM 4.2) at
day 4 after onset of clinical signs of the disease (Figure 1B).
The up-regulation of TREM2 was detected mainly in the
spinal cord, but not in the cortex and cerebellum, indicating
that TREM2 expression is associated with the inﬂammatory
lesions. The up-regulation of TREM2 on CD11bþcells was not
long lasting and returned back to almost normal levels at day
18 after onset of clinical EAE symptoms (Figure 1B).
Lentiviral Transduction of Bone Marrow–Derived Myeloid
Precursor Cells with TREM2
To study the involvement of microglial TREM2 in EAE, we
isolated bone marrow–derived myeloid precursors, lentivir-
ally transduced them with TREM2, and applied them as
putative precursors of microglia in diseased mice. Bone
marrow cells were isolated from female adult C57BL/6 mice
and cultured in GM-CSF–containing medium for 10–11 d.
Under these culture conditions, the number of CD11bþ cells
increased at least 20-fold as determined by counting the
CD11bþcells before and after culture. Flow cytometry analysis
of the cultured BM-MC showed expression of CD45, CD11b,
CD11c, CD36, and F4/80 (Figure 2A). No expression of MHC
class II, CD80, CD86, CD133, Sca1, and c-kit (CD117) was
detected, indicating that BM-MC still have an immature
phenotype, but without expressing stem cell surface markers
(Figure 2A). Importantly, no cell surface expression of the
microglial receptor TREM2 was detected (Figure 2), and very
low levels of TREM2 gene transcripts were observed (Figure 2).
However, RT-PCR demonstrated gene transcripts of the
TREM2-associated signaling molecule DAP12 (Figure 2). To
study the role of the microglial receptor TREM2 on myeloid
cells in EAE, we transduced BM-MC with a lentiviral vector
expressing both TREM2 and the marker GFP under two
distinct CMV promoters or a corresponding control GFP
vector (Figure 2B). Transduction efﬁciency of BM-MC by
vesicular stomatitis virus-G protein–pseudotyped lentiviral
vectors was regularly greater than 90% (Table S1). The
genetically modiﬁed myeloid precursor cells exhibited gene
transcripts and protein expression of TREM2 as demonstrated
by RT-PCR and ﬂow cytometry analysis (Figure 2C and 2D).
Increased Phagocytosis and Anti-Inflammatory Cytokine
Signaling by TREM2-Transduced Myeloid Precursors In
Vitro
Stimulation of TREM2 has been shown to induce phag-
ocytosis in primary microglia [14]. In order to determine the
effects of TREM2 expression on phagocytic activity of BM-
MC, we analyzed phagocytosis of microsphere beads and
apoptotic cells by TREM2-transduced BM-MC. Phagocytosis
of microsphere beads was increased in TREM2-stimulated
TREM2-transduced BM-MC compared to control BM-MC and
cultured monocytes (Figure 3A). Likewise, phagocytosis of
apoptotic membrane fragments derived from mixed neuron-
enriched cultures was increased after gene transduction of
TREM2. In detail, 93.3% (SEM 6.6) of BM-MC phagocytosed
apoptotic neurons after transduction with TREM2, while only
50.5% (SEM 5.6) of BM-MC phagocytosed apoptotic neurons
after transduction with the control GFP vector (Figure 3A).
Increased phagocytosis of beads and apoptotic cells after
TREM2 stimulation was completely neutralized by the ERK
inhibitor PD98059, suggesting that ERK signaling was
involved in TREM2-mediated phagocytosis by BM-MC (Figure
3A). TREM2 cross-linking antibodies stimulated phosphor-
ylation of ERK in TREM2-transduced BM-MC (Figure 3), but
did not modify cell surface expression of MHC class II, CD80,
CD86, CD36, CCR7, and CD11c (Figure S1).
Next, we asked whether phagocytosis is associated with
Figure 1. Expression Profile of TREM2 in Normal and Diseased CNS
(A) Flow cytometry analysis of TREM2 (open tracings) expression on
CD11bþ cells derived from the cortex of normal and EAE-diseased mice
at day 4 after onset of clinical symptoms as well as from EAE-diseased
mice at day 18 after onset of clinical symptoms. Isotype controls are
shown in grey-filled tracings. TREM2 expression is detected on CD11bþ
microglia/macrophages in the cortex of EAE-diseased mice. The
percentages of TREM2þ cells are indicated in the upper-right corner of
each histogram. Selected representative histograms are shown.
(B) Quantitative analysis of TREM2 expression on microglia by flow
cytometry gated for CD11bþcells. TREM2 expression is detected only on
a minority of microglia and perivascular macrophages in the normal CNS
tissue, but is up-regulated and detected in the spinal cord on the
majority of CD11bþcells at day 4 after onset of clinical symptoms of EAE.
Data are presented as mean 6 SEM. Tissues were derived from four EAE
and four normal mice.
doi:10.1371/journal.pmed.0040124.g001
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tion. Stimulation of TREM2-transduced BM-MC by solely
TREM2-speciﬁc antibody did not modulate gene transcrip-
tion of inﬂammatory mediators (Figure S1). Therefore, we
studied the effect of TREM2 stimulation on LPS-treated BM-
MC. Quantitative real-time RT-PCR of several cytokines was
performed 48 h after TREM2 cross-linking of TREM2-
transduced BM-MC and control GFP vector–transduced
BM-MC, which have been stimulated with 100 ng/ml LPS.
Interestingly, stimulation by TREM2 antibody 1 h before LPS
treatment showed increased IL-10 (5.7-fold [1.3 SEM]) and
decreased interleukin-1b (IL-1b; 0.5-fold [0.1 SEM]) gene
transcription in TREM2-transduced BM-MC compared to
control GFP vector–transduced BM-MC (Figure 3B). More-
over, we investigated gene transcript levels of cytokines in
BM-MC cocultured for 48 h with apoptotic mixed neuron-
enriched cultures. Gene transcripts of IL-1b and nitric oxide
synthase-2 (NOS2) were decreased in TREM2-transduced BM-
MC after challenge with apoptotic cells (Figure 3B). Trans-
duction by TREM2 enabled BM-MC to release a substantial
amount of IL-10 after stimulation as determined by ELISA
(Figure 3D). In detail, TREM2-transduced BM-MC released
130 pg/ml IL-10 (SEM 52) after stimulation with LPS- and
TREM2-speciﬁc antibodies (Figure 3D).
Selective Migration of TREM2-Transduced Myeloid Cells to
Inflammatory Lesions
We also analyzed migration of TREM2 or control GFP
vector–transduced BM-MC into the CNS after application in
Figure 2. Characterization and TREM2 Transduction of BM-MC
(A) Flow cytometry analyses of BM-MC. Bone marrow cells were cultured for 10 d in GM-CSF–containing medium and then analyzed by flow cytometry
with specific antibodies (open tracings) directed against CD45, CD11b, CD11c, MHC class II, CD80, CD86, F4/80, CD36, TREM2, Sca1, c-kit, and CD133.
Cells showed expression of CD45, F4/80, CD11b, CD11c, and CD36. The percentage of positive cells is indicated in the upper-right corner of each
histogram. Isotype controls are shown in grey-filled tracings.
(B) Lentiviral vector design. To express TREM2 in BM-MC, the mouse TREM2 coding sequence was cloned under the CMV promoter followed by a
second CMV promoter and GFP (plenti TREM2). The same vector without TREM2 was used as a control (plenti GFP).
(C) Gene transcripts in myeloid cells transduced with TREM2 vector (TREM2-BM-MC) or control GFP vector (GFP-BM-MC) for TREM2, DAP12, and the
housekeeping gene GAPDH were analyzed by RT-PCR. Gene transcripts for TREM2 were strongly detected in TREM2-BM-MC and weakly in GFP-BM-MC.
Both TREM2-transduced myeloid cells and control GFP vector–transduced myeloid cells showed gene transcription for DAP12, the TREM2 adapter and
signaling molecule.
(D) Flow cytometry analysis of TREM2-transduced BM-MC (bold line) and GFP-transduced BM-MC (narrow line), both labeled with TREM2-specific
antibodies. Isotype control antibody is shown in filled grey. Cell surface expression of TREM2 was detected on myeloid cells after lentiviral transduction
with TREM2, but not on control GFP vector–transduced myeloid cells.
doi:10.1371/journal.pmed.0040124.g002
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Debris Clearance by TREM2 in EAEmice intravenously. In healthy mice, no GFPþ cells were
detected on the microscopic level in the CNS tissue after
injection of 5310
6 BM-MC. Likewise, we failed to detect GFP-
transducedBM-MCintheCNSofmiceafﬂictedbyEAE,when5
3 10
6 cells were injected intravenously at day 1 after
appearance of the ﬁrst clinical symptoms. Then, we injected 5
3 10
6 TREM2 or control GFP vector–transduced BM-MC
intravenously into EAE-diseased mice at 4 d after onset of ﬁrst
clinical symptoms, at a time period reﬂecting the peak of the
disease.TheGFPþcellsweredetectedinthespinalcordofEAE-
diseased mice, preferentially in perivascular inﬂammatory
lesions (Figure 4A). In detail, analysis of inﬂammatory
perivascular EAE lesions at day 2 after cell therapy with
TREM2-BM-MC demonstrated a density of 261 cells/mm
2 of
invaded GFPþ cells (standard deviation [SD] 82). The majority
(86%) of invaded TREM2-BM-MC was located within the
perivascular area with a distance of less than 50 lmf r o mt h e
vesselwall.Asubstantialproportion(14%)oftheinvadedGFPþ
cells was also detected within the spinal cord parenchyma.
Invaded myeloid cells were round in shape and were clearly
positive for the common hematopoietic surface marker CD45
(Figure 4A), but not for the microglial typical marker Iba1
(Figure 4B). Myeloid cells applied intravenously migrated into
the spinal cord lesions within 2 h (Figure 4C), indicating that
they did not home in to other organs before entering the
nervous tissue. No difference in the amount of invaded cells
in EAE lesions was detected when comparing TREM2-
transduced and control GFP vector–transduced BM-MC
(Figure 4C). The cells were detected in the spinal cord for
2–3 d after administration. Finally, we did not detect
substantial numbers of GFPþ cells in the spinal cord at day
4 after injection (Figure 4C). At day 7, no GFPþ cells were
detected in the spinal cord, indicating that they either
underwent apoptosis or migrated away from the spinal cord.
Next, ﬂow cytometry analysis of GFPþ cells isolated from the
spinal cord was performed. Myeloid cells transduced with
TREM2 showed expression of TREM2 within the spinal cord
tissue, while no TREM2 expression was detected on GFP-
transduced cells (Figure 4D). At day 4 after injection of BM-
MC in EAE-diseased mice, 40.0% (SEM 7.2) of GFPþ cells
showed reduced CD45 antigen expression compared to BM-
MC before intravenous application (Figure 4E). Thus, BM-MC
migrated into the spinal cord independently of TREM2
expression and showed down-regulated CD45 expression, but
did not acquire a mature microglial phenotype and failed to
show long-lasting engraftment.
Tissue Debris Clearance and Creation of an Anti-
Inflammatory Cytokine Milieu by TREM2-Transduced
Myeloid Cells
Since TREM2-transduced BM-MC showed increased phag-
ocytosis of apoptotic cells and suppressed pro-inﬂammatory
gene transcription in vitro, we tested their in vivo potential in
clearance of tissue debris in EAE. In total, 5 3 10
6 myeloid
cells transduced either with TREM2 or with the control GFP
vector, or with PBS alone, were injected intravenously in
Figure 3. Myeloid Cells Transduced with TREM2 Showed Increased
Phagocytic and Anti-Inflammatory Activity In Vitro
(A) TREM2-transduced myeloid cells showed increased phagocytosis of
beads and of apoptotic neuron–enriched cultures. Analysis of the
phagocytosis of beads (left graph), TREM2-transduced myeloid cells
(open bars), control GFP vector–transduced myeloid cells (filled bars), or
cultured monocytes (grey bars) after stimulation with TREM2-specific
antibodies either untreated ( ) or treated with ERK inhibitor (þ).
Phagocytosis assay (right graph) of apoptotic cells derived from
neuron-enriched cultures by TREM2-transduced myeloid cells (open
bars), control GFP vector–transduced myeloid cells (filled bars), or
cultured monocytes (grey bars), either treated with ERK inhibitor (þ)o r
untreated ( ). Transduction of myeloid cells (BM-MC) with TREM2
increased the phagocytosis of beads and apoptotic cells that were
dependent on ERK phosphorylation. Data are presented as mean 6 SEM.
Unpaired t-test: p , 0.001 (TREM2 versus GFP) for BM-MC without ERK
inhibitor and with bead phagocytosis, and p , 0.001 (TREM2 versus GFP)
for BM-MC without ERK inhibitor and with phagocytosis of apoptotic
neurons. Five independent experiments were performed, and each of
them was done in quadruplicate.
(B) Anti-inflammatory activity of TREM2 stimulation. Myeloid cells were
transduced with TREM2 (open bars) or control GFP vector (filled bars).
Myeloid cells were cultured on plates coated with TREM2 cross-linking
antibodies (left graph). One hour later, cells were stimulated with LPS.
Gene transcript levels for TNFa, IL-1b, NOS2, and IL-10 were quantified by
real-time PCR after 48 h. TREM2-transduced myeloid cells showed
reduced gene transcript levels of IL-1b and NOS2 and an increased level
of IL-10. In addition, apoptotic cells derived from neuron-enriched
cultures were added to myeloid cells (right graph). Gene transcript levels
for TNFa, IL-1b, NOS2, and IL-10 were quantified by real-time PCR after 48
h. Data are presented as mean 6 SEM. Unpaired t-test: p , 0.001 (TREM2
versus GFP) with TREM2 plus LPS for IL-1, p¼0.0205 (TREM2 versus GFP)
with TREM2 plus LPS for IL-10, p ¼ 0.0149 (TREM2 versus GFP) with
coculture for IL-1, and p ¼ 0.012 (TREM2 versus GFP) with coculture for
NOS2. Four independent experiments were performed.
(C) Phosphorylation of ERK after stimulation of TREM2. Myeloid cells were
transduced with TREM2 and cultured for 1 h on plates coated with
TREM2 cross-linking antibodies (þ) or isotype control antibodies ( ).
Cross-linking of TREM2 increased the amount of phosphorylated ERK
(phospho ERK) in relation to total ERK (ERK).
(D) TREM2-transduced myeloid cells showed an increased release of IL-10
after stimulation of TREM2 plus LPS or coculture with apoptotic neuron–
enriched cultures. Myeloid cells were transduced with TREM2 (open bars)
or with control GFP vector (filled bars), cultured on plates coated with
TREM2 cross-linking antibodies, and stimulated with LPS 1 h later or
supplemented with apoptotic cells derived from neuron-enriched
cultures. The amount of IL-10 released in the supernatant was
determined by ELISA. Data are presented as mean 6 SEM. Unpaired t-
test: p ¼ 0.044 (TREM2 versus GFP) for TREM2 plus LPS, and p ¼ 0.0054
(TREM2 versus GFP) for coculture. Four independent experiments were
performed.
doi:10.1371/journal.pmed.0040124.g003
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Debris Clearance by TREM2 in EAEEAE-diseased mice at day 4 after disease onset. No difference
in the number of inﬁltrating T cells (CD3) and macrophages
(MAC3) into the nervous tissue was detected at day 2 after
application of TREM2-transduced cells, GFP-transduced cells,
or PBS control (Figure 5A and 5B; Table 1). To determine
phagocytosis in situ, we analyzed the lysosomal activity within
the inﬂammatory spinal cord lesions by immunostaining of
methanol-ﬁxed tissue with antibody directed against Lamp2.
An increased number of cells showing Lamp2 staining was
detected in the spinal cord of EAE-diseased mice at day 2
after treatment with TREM2-transduced myeloid cells (37.5
[SEM 4.2] cells/mm
2) compared to mice treated with GFP-
transduced myeloid cells (11.0 [SEM 3.1] cells/mm
2) or vehicle
control (7.7 [SEM 0.9] cells/mm
2) (Figure 5A and 5B). These
data indicated that TREM2-transduced myeloid cells show
increased lysosomal degradation associated with phagocytosis
of debris.
Next, we investigated in vivo the distribution of degen-
erated myelin basic protein (MBP) immunoreactivity, which
has been phagocytosed and degraded in lysosomes by myeloid
cells in inﬂammatory lesions. Degenerated MBP was detected
with a speciﬁc antibody directed against an epitope un-
masked during the process of myelin degeneration [22]. The
number of cells immunostained for degenerated MBP in the
spinal cord of EAE-diseased mice was reduced at day 2 after
treatment with TREM2-transduced myeloid cells (34.5 [SEM
3.5] cells/mm
2) compared to mice treated with GFP-trans-
Figure 4. Migration of TREM2-Transduced Myeloid Cells into EAE Lesions
(A) Detection of invaded myeloid cells in the spinal cord of EAE-diseased mice. Histological sections were obtained at day 2 after intravenous injection
of GFP-transduced cells in EAE-diseased mice. Myeloid cells were injected at day 4 after first clinical signs of EAE. Sections were labeled with CD45-
specific antibodies. Injected myeloid cells expressed CD45 and accumulated in inflammatory lesions. Scale bar indicates 50 lm.
(B) No Iba1 antigen was detected on invaded myeloid cells by double immunofluorescence labeling. GFPþcells were analyzed in the spinal cord of EAE-
diseased mice 4 d after intravenous injection of GFP-transduced myeloid cells. Myeloid cells were applied 4 d after first clinical signs of the disease.
Invaded cells showed round appearance, reminiscent of activated macrophage/microglial cells. Scale bar indicates 10 lm.
(C) Quantification of cells invaded into the spinal cord of EAE-diseased mice. TREM2-transduced BM-MC or GFP-transduced BM-MC were injected
intravenously at day 4 after the first clinical signs of the disease appeared. The BM-MCs migrated into spinal cord lesions within 2 h after intravenous
application and remained there for 2–4 d. No GFPþcells were detected within the spinal cord at day 7 after intravenous application. Data are presented
as mean 6 SEM.
(D) Flow cytometry analysis of TREM2 expression on TREM2-transduced and GFP-transduced myeloid cells obtained from the spinal cord of EAE-
diseased mice at day 2 after application. Expression of TREM2 was detected on myeloid cells transduced with TREM2 (red tracing), but not on cells
transduced with GFP (green tracing). Tracings shown are from cells gated for GFP. Control antibody isotype is shown as grey-filled tracing.
(E) Flow cytometry analysis of CD45 expression on GFP-transduced myeloid cells before injection (green tracing) and on GFPþ cells invaded into the
spinal cord (red tracing) at day 4 after injection. Engrafted myeloid cells showed reduced levels of CD45 expression, reminiscent of microglia. Tracings
shown are from cells gated for GFP. Control antibody isotype is shown as grey-filled tracing.
doi:10.1371/journal.pmed.0040124.g004
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Debris Clearance by TREM2 in EAEFigure 5. Increased Phagocytic Activity and Removal of Degenerated Myelin in the Spinal Cord by TREM2-Transduced Myeloid Cells
(A) Immunostaining of macrophages (MAC3), T cells (CD3), degenerated MBP (dMBP), and Lamp2 in the spinal cord of EAE-diseased mice at day 2 after
injection of TREM2-transduced myeloid cells (TREM-BM-MC), GFP-transduced myeloid cells (GFP-BM-MC), or vehicle control (PBS). Cells were injected
intravenously in EAE-diseased mice at day 4 after first clinical signs of the disease. Scale bars for MAC3 and CD3 indicate 300 lm. Scale bars for dMBP
and Lamp2 indicate 50 lm.
(B) Quantification of the number of MAC3- and CD3þcells, degenerative MBP, and LAMP2-positive cells. EAE-diseased mice were injected at day 4 after
first clinical signs of the disease with TREM2-transduced myeloid cells (TREM2-BM-MC), GFP-transduced myeloid cells (GFP-BM-MC), or vehicle control
(PBS). At day 2 after cell injection, spinal cords were removed, stained, and analyzed. Macrophages were labeled by MAC3 and T cells by CD3-specific
antibodies. Cell therapy by myeloid precursors did not affect the spinal cord immune cell infiltrates. Furthermore, quantification of cells stained for
degenerated MBP (dMBP) in the spinal cord of EAE-diseased mice at day 2 after injection was performed, and the amount of degenerated MBP was
reduced by cell therapy with TREM2-transduced myeloid cells. Quantification of Lamp2-positive cells (LAMP2) in spinal cord lesions of EAE-diseased
mice at day 2 after cell injection was performed. The number of Lamp2-positive cells showing phagocytic activity was increased by the intravenous
injection of TREM2-BM-MC. For quantitative analysis, three lumbar spinal cord sections of three mice per group were examined. Data are presented as
mean 6 SEM. ANOVA, followed by unpaired t-test: p ¼ 0.0422 (TREM2 versus GFP) for dMBP, and p ¼ 0.0069 (TREM2 versus GFP) for LAMP2.
(C) Anti-inflammatory cytokine milieu in the spinal cord after treatment with TREM2-transduced myeloid cells. Real-time RT-PCR of cytokines and
growth factors at day 6 after first clinical signs of the disease and 2 d after injection of TREM2-transduced myeloid cells (n ¼ 3), control GFP vector–
transduced myeloid cells (n ¼ 3), or PBS as vehicle control (n ¼ 3). Relative gene transcript levels of TNFa, IFNc, and IL-1b were decreased. ANOVA
followed by unpaired t-test: p¼0.0324 (TREM2 versus GFP) for TNFa, p¼0.0111 (TREM2 versus PBS) for TNFa, p¼0.0068 (TREM2 versus PBS) for IFNc,
and p ¼ 0.0215 (TREM2 versus PBS) for IL-1b. Each PCR experiment was performed in quadruplicate.
doi:10.1371/journal.pmed.0040124.g005
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Debris Clearance by TREM2 in EAEduced myeloid cells (50.5 [SEM 1.5] cells/mm
2) or vehicle
control (48.0 [SEM 9.0] cells/mm
2) (Figure 5A and 5B).
Finally, we analyzed whether increased phagocytosis by
TREM2-transduced myeloid cells is also associated with an
anti-inﬂammatory cytokine milieu in the spinal cord lesions.
Quantitative RT-PCR analysis at day 2 after cell injection
demonstrated a signiﬁcant decrease of gene transcription of
tumor necrosis factor-a (TNFa), interferon-c (IFNc), and IL-
1b, and an increase of gene transcript of IL-10 (3.7-fold) in
the spinal cord of the TREM2-BM-MC–injected EAE-diseased
mice (Figure 5C). Creation of an anti-inﬂammatory cytokine
milieu was solely detected within the spinal cord, but not in
secondary lymphoid organs such as the spleen and lymph
nodes (Figure S2), indicating that TREM2-transduced myeloid
cells speciﬁcally acted within the CNS. Furthermore, a change
in the spinal cord cytokine proﬁle was later followed by a
slightly decreased number of inﬁltrating immune cells. In
detail, at day 14 after treatment, 180.7 (SEM 41.5) CD3þcells/
mm
2 and 146.7 (SEM 62.1) MAC3þcells/mm
2 were counted in
the spinal cord tissue of TREM2-BM-MC–treated animals,
while 264.3 (SEM 54.8) CD3þ cells/mm
2 and 262.3 (SEM 30.8)
MAC3þ cells/mm
2 were observed in GFP-BM-MC–treated
mice (Table 1).
Disease Amelioration and Reduced Tissue Damage by
TREM2-Transduced Myeloid Precursor Cells
TREM2-transduced BM-MC showed an effect on the EAE
disease course, leading to early and almost complete recovery
from clinical symptoms. In total, 5 3 10
6 BM-MC were
injected intravenously at day 4 after onset of ﬁrst clinical
symptoms of EAE, which coincides with the disease peak with
ongoing tissue destruction. Already 2 days after cell injection,
mice improved in clinical performance (Figure 6A). At 7 days,
the mean clinical score was reduced from 2.5 (SD 0.4) after
GFP-transduced BM-MC application to 1.3 (SD 0.1) after
TREM2-transduced BM-MC application (Figure 6A; Table
S2). While no difference was detectable in the cumulative
clinical score before and on the day of cell injection, the
cumulative clinical score was reduced from 33.8 (SD 2.5) after
injection of 5 3 10
6 GFP-transduced BM-MC to 17.6 (SD 6.0)
after injection of 5 3 10
6 TREM2-transduced BM-MC (Table
S2). Importantly, no changes in either the disease course or in
cumulative clinical scores were observed in PBS-injected mice
and control GFP vector–transduced BM-MC–injected animals
(Table S2). TREM2-transduced BM-MC were only effective in
ameliorating the disease symptoms if injected at day 4 after
onset of clinical symptoms. TREM2-transduced cells injected
at day 1 after clinical onset of EAE did not interfere with the
disease course, indicating that TREM2-tranduced BM-MC do
not prevent the initiation phase of EAE, but act during the
recovery and repair phase of the disease (Figure 6B). Finally,
we analyzed the effect of different cell amounts of TREM2-
transduced BM-MC. A reduced cell amount of 2 3 10
6
TREM2-transduced BM-MC was as effective in ameliorating
the clinical disease course as 5310
6 TREM2-transduced BM-
MC (Figure 6C).
Apart from its clinical effect, TREM2-transduced cells
protected and supported repair of the spinal cord tissue. At
day 14 after cell therapy with TREM2-transduced myeloid
cells, a clear reduction of axonal damage and demyelination
was detected as determined by immunostaining for APP,
dephosphorylated neuroﬁlament (SMI32), and staining of
myelin (LFB) (Figure 7A). In detail, mice treated with 5 310
6
TREM2-transduced BM-MC showed, at day 14 after cell
injection, fewer axonal APP-stained deposits per mm
2 (23.0
[SEM 4.6]) compared to either 5 3 10
6 GFP-transduced (41.6
[SEM 5.0]) or PBS-injected EAE-diseased mice (45.3 [SEM
16.0]) (Figure 7B). Likewise, the relative number of dephos-
phorylated axons was reduced to 6.8 (SEM 0.9) compared to
either GFP-transduced (16.3 [SEM 1.6]) or PBS-injected EAE
animals (16.5 [SEM 1.6]) (Figure 6B). In addition, TREM2-BM-
MC–treated mice revealed a reduced percentage of demyeli-
nation (1.8% [SEM 0.6]) compared to GFP-BM-MC–treated
mice (3.8% [SEM 0.2]) or PBS-treated mice (3.9% [SEM 0.3])
(Figure 7B). Thus, TREM2-transduced BM-MC–treated mice
showed a clear protective and repair-promoting effect on
spinal cord tissue in EAE.
Discussion
In this study, we have shown that intravenously applied
TREM2-transduced myeloid precursors ameliorate clinical
symptoms and induce recovery from EAE. The TREM2-
transduced myeloid cells migrated into the CNS lesions,
induced myelin debris clearance, and created an anti-
inﬂammatory cytokine milieu. The treated mice showed less
axonal injury and reduced demyelination. The data demon-
strate that TREM2þmyeloid cells are involved in tissue debris
clearance and resolution of inﬂammation and suggest a novel
approach to the therapy of neuroinﬂammatory disease.
Table 1. Histological Quantification of CNS Immune Cell Invasion
Histological
Analysis
Type of
Cells or PBS
Applied
Number of
Histological
Sections Analyzed
Number
of Mice
Analyzed
MAC3þ
Cells/mm
2
(SEM)
CD3þ
Cells/mm
2
(SEM)
Two days after cell or PBS injection TREM2-transduced myeloid cells 9 3 182.0 (29.4) 160.5 (9.4)
GFP-transduced myeloid cells 9 3 193.3 (29.0) 188.3 (49.3)
PBS control 9 3 173.5 (76.3) 164.7 (25.2)
Fourteen days after cell or PBS injection TREM2-transduced myeloid cells 9 3 146.7 (62.1) 180.7 (41.5)
GFP-transduced myeloid cells 9 3 262.3 (30.8) 264.3 (54.8)
PBS control 9 3 219.0 (39.7) 227.0 (16.9)
Intravenous injection of 5 3 10
6 cells or PBS at day 4 after the first clinical signs of EAE.
doi:10.1371/journal.pmed.0040124.t001
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Debris Clearance by TREM2 in EAETREM2 on microglia fulﬁlls an important function for CNS
tissue homeostasis. Loss-of-function mutations of TREM2 in
humans result in inﬂammatory neurodegeneration, loss of
myelin, basal ganglia calciﬁcation, and bone abnormalities
[23–25]. TREM2 is selectively expressed on immature den-
dritic cells, osteoclasts, and microglia, but not on monocytes
[21,26]. TREM2 in osteoclasts is involved in resorption of
bones, also requiring phagocytic activity [24,27]. In microglial
cells, TREM2 promotes phagocytosis and anti-inﬂammatory
cytokine signaling [14]. Recently, it has been shown that
TREM2 is expressed on macrophages inﬁltrating CNS tissue
from the circulation, and that TREM2 acts to inhibit cytokine
production by macrophages in response to several toll-like
receptor ligands [28].
In this study, we have demonstrated that the gene transfer
of TREM2 in bone marrow myeloid precursor cells supports
phagocytosis of beads and apoptotic neuronal cells and, in
addition, shows strong anti-inﬂammatory activity. Both
effects are required to promote the repair of injured CNS
tissue by engulﬁng tissue debris and shutting off inﬂamma-
tory processes. We injected the TREM2-transduced myeloid
cells into the circulation of EAE-diseased mice and detected
these cells in their spinal cord lesions as well as in the spleen,
but failed to detect any change in the cytokine proﬁle in the
spleen and lymph nodes. Possibly, the ligand of TREM2,
which appears to be a component of apoptotic neuronal cell
membranes [14], is not present in normal spleen and lymph
nodes, but is located in the spinal cord tissue that has the
lesion. The TREM2-transduced myeloid cells migrated into
the spinal cord lesions within 2 h following intravenous
application, showed increased lysosomal activity, cleared the
myelin debris, and created an anti-inﬂammatory cytokine
milieu within the spinal cord. The invaded myeloid cells
remained within the lesions for several days, but were not
detected after 1 wk, indicating that they either evaded the
lesions or underwent apoptosis or autophagy.
Our data show that TREM2 on myeloid cells supports an
essential function of the CNS tissue phagocytes. The
phagocytic function of macrophages and microglia has been
implicated in the removal of myelin debris during EAE [29].
Particularly, macrophages appear to fulﬁll an important role
in the clearance of tissue debris, since depletion of macro-
phages impairs CNS remyelination [30,31]. Rapid clearance of
myelin debris is required since components of the myelin
such as Nogo prevent axonal regeneration and axonal
remodeling [32]. Axonal remodeling has been shown to
contribute to recovery and repair in EAE [33]. Therefore, the
reduced amount of demyelination and axonal damage after
therapy with TREM2-transduced myeloid precursor cells
might also be partially explained by improved remyelination
and axonal remodeling via facilitated engulfment of myelin
debris. Alternatively, reduced demyelination and less axonal
injury after therapy with TREM2-transduced myeloid pre-
cursor cells could be a positive effect of the improved
resolution of inﬂammation and the anti-inﬂammatory cyto-
kine milieu, both limiting the inﬂammation-induced tissue
damage.
Furthermore, TREM2 of myeloid cells created an anti-
inﬂammatory cytokine milieu in the spinal cord of EAE-
diseased mice. Particularly, the gene transcript level of TNFa
was reduced, while that of IL-10 increased after application of
TREM2-transduced myeloid precursor cells. Increased gene
transcripts of IL-10 might be directly due to invaded TREM2-
transduced myeloid precursors stimulated within the lesion
sites, but we cannot exclude the possibility that TREM2-
transduced myeloid precursors act indirectly via a secondary
immune organ to stimulate a regulatory immune cell type
migrating into the CNS. IL-10 has profound regulatory effects
on the immune system and is vital for the recovery phase of
EAE. Interestingly, IL-10 gene transcripts are increased in the
CNS during the recovery phase of EAE [34]. IL-10 is involved
in the disease recovery and resolution of inﬂammation
Figure 6. TREM2-Transduced Myeloid Cells Ameliorated EAE
(A) Treatment of EAE-diseased mice by TREM2-transduced myeloid cells
at the peak of the disease. Clinical EAE score of mice injected at day 4
after first clinical signs of the disease (arrow) with TREM2-transduced
myeloid cells (black tracing), control GFP vector–transduced myeloid
cells (green tracing), or PBS (red tracing). Intravenous application of 5 3
10
6 TREM2-transduced myeloid cells ameliorated the clinical score of
EAE. Data are presented as mean 6 SD. Mice per group: n ¼ 6o rn ¼ 7.
ANOVA followed by unpaired t-test: p¼0.0015 (TREM2 versus GFP) and p
¼ 0.0063 (TREM2 versus PBS) at day 20; p ¼ 0.0045 (TREM2 versus GFP)
and p ¼ 0.0046 (TREM2 versus PBS) at day 30.
(B) TREM2-transduced myeloid cells injected at the onset of the disease
do not affect EAE. Clinical EAE score of mice injected 1 d after the first
clinical signs of the disease (arrow) with 5 3 10
6 TREM2-transduced
myeloid cells (black), 5 3 10
6 control GFP vector–transduced myeloid
cells (green), or PBS (red). No effect on the clinical EAE score was
observed. Data are presented as mean 6 SD. Mice per group: n ¼ 3.
(C) Treatment of EAE by TREM2-transduced myeloid cells. Clinical EAE
score of mice injected at day 4 after first clinical signs of the disease with
2 3 10
6 TREM2-transduced myeloid cells (black), 5 3 10
6 TREM2-
transduced myeloid cells (grey), or PBS control (red). Intravenous
application of 2 3 10
6 or 5 3 10
6 TREM2-transduced myeloid cells
ameliorated the clinical score of EAE. Data are presented as mean 6 SD.
Mice per group: n¼3. ANOVA followed by unpaired t-test: p¼0.0023 (2
310
6 cells versus PBS) and p¼0.0068 (5310
6 cells versus PBS) at day 20;
p ¼ 0.0107 (2 3 10
6 cells versus PBS) at day 30.
doi:10.1371/journal.pmed.0040124.g006
PLoS Medicine | www.plosmedicine.org April 2007 | Volume 4 | Issue 4 | e124 0685
Debris Clearance by TREM2 in EAEbecause remission is impaired in IL-10–deﬁcient mice [35].
Furthermore, the involvement of CD4þ CD25þ regulatory T
cells in the recovery from EAE can be narrowed to their
production of IL-10 [36]. Most importantly, exogenous
administration of IL-10 is only truly effective at ameliorating
EAE when targeted directly to the CNS [37]. Thus, IL-10
produced by the TREM2-transduced myeloid precursor cells
during engulfment of myelin debris might favor recovery
from EAE.
The TREM2-transduced myeloid cells were applied during
ongoing EAE at a time point when the antigen-priming
inﬂammatory phase has been completed and the recovery
phase started. No interference with immune cell inﬁltration
was observed at day 2 after cell injection since EAE-diseased
mice treated with TREM2-transduced myeloid cells showed
the same amount of inﬁltrating T cells and macrophages as
EAE animals injected with control GFP vector–transduced
myeloid cells. However, at day 14 after cell injection, EAE-
diseased mice treated with TREM2-transduced myeloid cells
demonstrated a slightly reduced number of MAC3þ macro-
phages and CD3þ T cells within the inﬂammatory lesions,
indicating that the cell therapy by TREM2-transduced
Figure 7. Application of TREM2-Transduced Myeloid Cells Reduced Axonal and Myelin Injury
(A) Reduced spinal cord axonal injury and decreased demyelination after cell therapy by TREM2-transduced myeloid cells. Axonal injury and damage
were analyzed by immunostaining with specific antibodies directed against APP and dephosphorylated neurofilament (SMI32) at day 14 after cell
application. Demyelination was determined by LFB staining at day 14 after cell application. Mice were injected at day 4 after first clinical signs of EAE by
TREM2-transduced myeloid precursor cells (TREM2-BM-MC), GFP-transduced BM-MC (GFP-BM-MC), or PBS control. Representative histological pictures
are shown. Scale bars for APP and LFB indicate 200 lm, and for inserts indicate 50 lm. Scale bar for SMI32 indicates 50 lm, and for insert indicates 20
lm.
(B) Quantification of axonal damage and demyelination 14 d after cell application in EAE with TREM2-transduced myeloid cells (black bars), control GFP
vector–transduced myeloid cells (green bars), or vehicle PBS control (red bars). Level of axonal injury (APP-positive deposits/mm
2), axonal damage
(relative number of SMI32-positive axons), and demyelination (loss of LFB, as a percentage) were significantly reduced after cell therapy with TREM2-
transduced BM-MC. For quantitative analysis, at least three lumbar spinal cord sections of three mice per group were investigated. Data are presented
as mean 6 SEM. ANOVA followed by unpaired t-test: p ¼ 0.0425 (TREM2 versus GFP) and p ¼ 0.0759 (TREM2 versus PBS) in APP; p ¼ 0.0012 (TREM2
versus GFP) and p ¼ 0.0098 (TREM2 versus PBS) in SMI32; p ¼ 0.0465 (TREM2 versus GFP) and p ¼ 0.00450 (TREM2 versus PBS) in LFB.
doi:10.1371/journal.pmed.0040124.g007
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TREM2-transduced myeloid cells did not improve clinical
symptoms of EAE, if applied at day 1 of clinical symptoms. We
failed to detect the GFP-labeled cells within the CNS after
application of cells at this early time point, indicating that
migration of cells into the lesion side is required for
therapeutic efﬁcacy.
EAE has been studied in DAP12-deﬁcient mice [38], which
might have impaired TREM2 signaling. While TREM2 of
myeloid precursor cells improved ongoing disease by possibly
acting locally within the CNS, DAP12-deﬁcient animals failed
to develop EAE due to impaired antigen priming during the
inﬂammatory phase [38]. Furthermore, myeloid precursor
cells used in our study failed to express MHC class II and
costimulatory molecules required for antigen presentation to
auto-reactive CD4þT cells. In this respect, myeloid precursor
cells were very similar to resting microglial cells, which lack
MHC class II and CD86 expression under normal conditions
[16].
In EAE, auto-reactive CD4þ TH1 cells secrete pro-
inﬂammatory cytokines such as IFNc and TNFa initiating a
CNS inﬂammatory reaction, which is then ampliﬁed within
the CNS by microglia [16,39,40]. The inﬂammatory phase is
either promptly resolved by shutting off inﬂammation or
deteriorates in a neurodegenerative phase, which involves
axonal and neuronal injury. This secondary progressive
neurodegenerative phase, particularly with axonal tissue loss,
appears to be resistant to anti-inﬂammatory therapies and
predicts the clinical outcome in MS patients [41,42]. Most
experimental approaches in EAE aim at skewing the cytokine
proﬁle of myelin-speciﬁc TH cells from TH1 to TH2 by
altered peptide ligands [43,44], hydroxymethyl-glutaryl coen-
zyme A reductase inhibitors (‘‘statins’’)[ 4 5 ] ,o rD N A
vaccination combined with gene delivery of interleukin-4
(IL-4) [46]. Neuroprotective and repair-promoting strategies
of EAE are relatively unexplored, most probably due to the
limited capacity of protein therapeutics to pass the blood–
brain barrier and enter the target tissue. Targeting of cells
into the lesioned CNS offers the possibility of a site-directed
cellular effect and local release of therapeutic proteins.
Genetically modiﬁed myelin-speciﬁc CD4þ TH1 cells over-
expressing the neurotrophic factor, nerve growth factor, have
been applied intravenously to treat EAE [47], but T cells were
auto-reactive in nature and nerve growth factor also acted
directly on immune cells such as monocytes.
Recently, brain-derived neurospheres have been injected
intravenously and have been successfully used for cell therapy
of EAE inducing repair and immunomodulatory activity
[48,49], but these adult neural precursors are not a suitable
cellular source for broad clinical applications. In contrast,
bone marrow is an accessible source of myeloid precursor
cells and, in addition, these cells can also be expanded to
sufﬁcient cell numbers from the peripheral blood of patients
following bone marrow mobilization. To create a microglia-
like phenotype, we transduced myeloid cells with the TREM2
receptor and treated EAE by intravenous cell injection.
Thus, we conclude that TREM2-transduced myeloid pre-
cursor cells applied intravenously ameliorate EAE either
locally inside the CNS or indirectly via another regulatory
immune cell type by clearance of tissue debris and resolution
of inﬂammation, thereby opening new avenues for cell
therapy of inﬂammatory and degenerative CNS diseases.
Supporting Information
Figure S1. TREM2-Transduced Myeloid Precursor Cells Lack Up-
Regulation of Immunoreceptors or Cytokines after Solely TREM2
Stimulation
(A) No change in cell surface immunoreceptor expression of BM-MC
after TREM2 stimulation. TREM2- or GFP-transduced BM-MC were
cultured on plates coated with a cross-linking antibody speciﬁc for
TREM2 or isotype control antibody. Cells were analyzed after 2 d of
stimulation by ﬂow cytometry. Stimulation of TREM2 did not change
cell surface expression of CD80, CD86, MHC class II, CD11c, CCR7,
and CD36. Grey ﬁlled line, negative control; blue line, TREM2-BM-
MC with TREM2 stimulation; red line, TREM2-BM-MC without
stimulation; green line, GFP-BM-MC with TREM2 stimulation; and
yellow line, GFP-BM-MC without stimulation.
(B) No change in cytokine gene transcription of BM-MC after solely
TREM2 stimulation. TREM2- or GFP-transduced BM-MC were
cultured on plates coated with a cross-linking antibody speciﬁc for
TREM2 or isotype control antibody. Cells were analyzed after 24 h of
stimulation by real-time RT-PCR of TNFa, IL-1b, NOS2, and IL-10 to
determine gene transcription of TREM2-transduced (open bars) and
control GFP vector–transduced (ﬁlled bars) myeloid cells after cross-
linking by TREM2-speciﬁc antibodies. No change in gene transcript
levels of inﬂammatory mediators was detected after stimulation of
TREM2 solely. Data are presented as mean 6 SEM, n ¼ 4.
Found at doi:10.1371/journal.pmed.0040124.sg001 (1.7 MB PDF).
Figure S2. Therapy of EAE by TREM2-Transduced Myeloid Cells Did
Not Change the Cytokine Proﬁle within the Spleen and Lymph Nodes
The cytokine gene transcript levels in the spleen (A) and lymph nodes
(B) were unchanged after injection of TREM2-transduced cells into
EAE-diseased mice. Real-time RT-PCR of pro-inﬂammatory cytokines
was performed at day 6 after ﬁrst clinical signs of the disease and 2 d
after injection of TREM2-transduced myeloid cells (n ¼ 3), control
GFP vector–transduced myeloid cells (n¼3), or PBS as vehicle control
(n ¼ 3). Gene transcript levels of TNFa, IFNc, IL-1b, IL-4, IL-10, and
NOS2 were unchanged. Data are presented as mean 6 SEM.
Found at doi:10.1371/journal.pmed.0040124.sg002 (3.6 MB PDF).
Table S1. Transduction Efﬁciency of BM-MC by Lentiviral Vectors
Found at doi:10.1371/journal.pmed.0040124.st001 (24 KB DOC).
Table S2. Disease Scores of EAE
Found at doi:10.1371/journal.pmed.0040124.st002 (39 KB PDF).
Table S3. Oligonucleotide Sequences Used in This Study
Found at doi:10.1371/journal.pmed.0040124.st003 (29 KB PDF).
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Background. Multiple sclerosis (MS) is a progressive disease of the
central nervous system (CNS; the brain and spinal cord) in which
communications within the brain are disrupted. In healthy individuals,
the brain controls the body by sending electrical messages along nerve
fibers. Like electrical wires, these fibers have to be insulated to allow the
efficient transfer of electrical impulses. This insulation is provided by
myelin, a fatty tissue that surrounds the nerve fibers. In patients with MS,
patchy myelin loss, inflammation, and scarring (sclerosis) disrupt nerve
transmissions, causing weakness or paralysis of the limbs, balance and
coordination problems, and numerous other symptoms. The damage to
the myelin (which increases over time) is caused by the patient’s immune
system, but what triggers this abnormal behavior is unclear. There is no
cure for MS, but drugs that modulate the immune system (for example,
interferons and steroids) can slow its progression.
Why Was This Study Done? Any treatment for MS needs to limit tissue
destruction by the immune system and to promote the repair of the
damaged myelin and nerve fibers. Although researchers have identified
some agents that promote nerve repair, it is difficult to get them into the
CNS, which is protected by an impermeable barrier. However, some cell
types can migrate into the CNS so it might be possible to adapt them as
delivery vehicles for therapeutic agents. In this study, the researchers
investigated whether bone marrow–derived myeloid precursor cells (a
source of several immune system cell types) might be useful for the
treatment of MS, both as delivery vehicles and as a source of cells that
can resolve inflammation and clear cellular debris from sites of myelin
destruction; this clearance has to occur before nerves and myelin can be
repaired. Myeloid precursor cells, the researchers reasoned, might satisfy
both these requirements because they naturally migrate into the CNS
where some turn into microglia, immune system cells that engulf and
digest cellular debris.
What Did the Researchers Do and Find? The researchers isolated
myeloid precursor cells from mouse bone marrow and induced the
expression of triggering receptor expressed on myeloid cells-2 (TREM2, a
protein made by microglia) in them using a viral vector. They injected
these TREM2-expressing cells into the veins of mice with experimental
autoimmune encephalomyelitis (EAE, an animal model of MS) and
examined their migration into the spinal cord, their effect on EAE
symptoms, and their effect on cell debris clearance and inflammatory
responses in spinal cord lesions. Neither TREM2-expressing nor control
myeloid precursor cells migrated into the spinal cord when injected into
healthy mice or into animals just beginning to show the symptoms of
EAE. However, both cell types migrated into the spinal cord when
injected into animals when EAE symptoms were at their peak. The
injection of TREM2-expressing myeloid precursor cells (but not control
myeloid precursor cells) at this time reduced EAE symptoms and nerve
damage, and halted myelin loss. It also increased the clearance of cell
debris and myelin fragments and created an anti-inflammatory environ-
ment in the spinal cord lesions.
What Do These Findings Mean? These findings indicate that the
intravenous injection of bone marrow–derived myeloid precursor cells
engineered to express TREM2 can reduce clinical symptoms and induce
recovery in mice with EAE. Whether the TREM2-expressing myeloid
precursor cells act locally in the CNS or indirectly via other immune
system cells is not clear yet. In addition, the findings need to be
replicated in more animals before this approach is tested in people.
Nevertheless, the intravenous injection of cells of this type could provide
a two-pronged approach to the treatment of MS (and other neuro-
inflammatory diseases). First, bone marrow–derived myeloid precursor
cells that have been engineered to express TREM2 could help to treat MS
by clearing tissue debris and reducing inflammation in spinal cord
lesions. Second, the same cells could be used to deliver agents to the
lesions that promote nerve repair. Importantly, these results suggest that
TREM2-expressing myeloid precursor cells might have the potential to
treat MS after the onset of clinical symptoms, an important consideration
for a chronic disease that often indicates relapses by new clinical
symptoms.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040124.
  US National Institute of Neurological Disorders and Stroke patient
information on multiple sclerosis (in English and Spanish)
  UK National Health Service health encyclopedia information on
multiple sclerosis
  MedlinePlus encyclopedia pages on multiple sclerosis
  The US National MS Society information on multiple sclerosis for
patients and professionals (in English and Spanish)
  UK MS Society information on multiple sclerosis for patients and
professionals
  Multiple Sclerosis International Federation information on multiple
sclerosis for patients, caregivers, and professionals (in English, Arabic,
German, Spanish, French, Italian and Russian)
PLoS Medicine | www.plosmedicine.org April 2007 | Volume 4 | Issue 4 | e124 0689
Debris Clearance by TREM2 in EAE